New Phase 3 Study Finds Johnson & Johnson's (JNJ) XARELTO Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots
Tweet Send to a Friend
Johnson & Johnson (NYSE: JNJ) saw Janssen Pharmaceuticals, Inc. (Janssen) announce new Phase 3 results from EINSTEIN CHOICE showing patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
